Welcome to our dedicated page for Iteos Therapeutics SEC filings (Ticker: ITOS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The iTeos Therapeutics, Inc. (ITOS) SEC filings page on Stock Titan provides access to the company’s historical regulatory documents, including annual and quarterly reports, current reports on Form 8-K, and specialized forms related to its change in status as a public company. These filings offer detailed information on iTeos’ immuno-oncology pipeline, clinical collaborations, strategic decisions, and corporate transactions.
For investors and researchers examining iTeos, Forms 10-K and 10-Q (where available) describe the company’s business, risk factors, and financial condition, including discussion of programs such as belrestotug, EOS-984, EOS-215, and inupadenant, and its focus on the TIGIT/CD226 axis, the adenosine pathway, ENT1, TREM2, and PTPN1/2. Form 8-K filings capture material events, such as the May 2025 decision to wind down operations, the July 2025 Agreement and Plan of Merger with Concentra Biosciences, and the August 29, 2025 completion of the tender offer and merger that made iTeos a wholly owned subsidiary of Concentra.
Regulatory status changes are documented in Form 25, filed by Nasdaq on August 29, 2025, which notified the SEC of the removal of iTeos’ common stock from listing on The Nasdaq Stock Market LLC, and in Form 15, filed by iTeos on September 8, 2025 to terminate registration of its common stock under Section 12(g) of the Exchange Act and suspend reporting obligations under Sections 13 and 15(d). Together, these filings show that ITOS is no longer a listed or reporting security.
On Stock Titan, these documents are supplemented by AI-powered summaries that highlight key points from lengthy filings, helping readers quickly understand major developments such as the structure of the Concentra transaction, the terms of the contingent value rights, and the implications of delisting and deregistration. Users can review historical SEC disclosures to analyze how iTeos’ clinical strategy, financial position, and corporate structure evolved leading up to its acquisition and transition from a public to a privately held company.
Overview The Company disclosed termination of the GSK collaboration and the belrestotug program (GSK Termination Notice dated 2025-05-13; Mutual Termination Agreement dated 2025-07-18 with a $32.0 million settlement payable). On 2025-05-28 the Company announced intent to wind down clinical and operational activities, expected substantially complete in Q3 2025. The registrant reported substantial doubt about its ability to continue as a going concern as of the issuance date of these financial statements (2025-08-06).
Key financials
- Cash and cash equivalents: $207.820 million; short-term investments: $307.610 million; long-term investments: $74.614 million; total assets: $623.083 million.
- Total liabilities: $129.282 million; unrecognized tax benefits: $48.790 million; grants repayable: $6.606 million.
- Six months ended 6/30/2025 net loss: $113.341 million; three months ended 6/30/2025 net loss: $78.729 million; basic net loss per share: $(2.61) six months, $(1.81) quarter.
- Operating highlights: R&D expense $86.314 million YTD; restructuring costs $16.335 million in the quarter; license and collaboration revenue $0 in 2025 vs $35.0 million in H1 2024.
iTeos Therapeutics (ITOS) has signed a definitive Agreement & Plan of Merger (7/18/25) with Concentra Biosciences. Parent launched a tender offer at $10.047 in cash per share plus one non-transferable CVR for each share.
- CVR payments: (i) 100 % of closing net cash above $475 m; (ii) 80 % of net proceeds from a sale/licence of specified legacy programs if a disposition occurs within 6 months post-close and cash is received within 8 years.
- Offer expires 23:59 ET on 8/28/25; may be extended, outside date 10/16/25.
- Key closing conditions: >50 % shares tendered, minimum closing net cash ≥ $475 m, no legal restraints, reps & warranties accurate. No financing condition; Tang Capital provides a limited guaranty up to $465 m.
- iTeos board unanimously recommends tendering; TD Cowen rendered a fairness opinion.
- Termination fee: $8.4 m; expense reimbursement cap $0.5 m.
- Equity treatment: in-the-money options & certain RSUs cashed out (cash + CVR); out-of-the-money options cancelled.
- Golden-parachute estimates: Detheux $4.1 m, Call $1.9 m, Feltquate $1.2 m.
- D&O indemnification maintained 6 yrs; “tail” insurance premium capped at 200 % of current cost.